NCT00908206View on ClinicalTrials.gov

Effects of GSK598809 on Brain Activation in Abstinent Alcoholics

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2009

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Substance DependenceAlcohol Dependence
Interventions
DRUG

GSK598809

Subjects will receive a single 175 mg oral dose of GSK598809.

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY